Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18597990 | CRYSTALLINE FORMS OF A NEUROACTIVE STEROID | March 2024 | June 2024 | Allow | 3 | 0 | 0 | No | No |
| 18389393 | 4,4-DIVINYLAZOARYLENE-BRIDGED DIRUTHENIUM COMPLEX BEARING Ru(CO)CL(PiPr3)2 AS AN INORGANIC CATALYST | November 2023 | April 2024 | Allow | 5 | 1 | 0 | No | No |
| 18389129 | 4,4'-DIVINYLAZOBENZENE-BRIDGED DIRUTHENIUM COMPLEX BEARING Ru(CO)Cl(PiPr3)2 MOIETIES AS AN INORGANIC CATALYST | November 2023 | March 2024 | Allow | 4 | 1 | 0 | No | No |
| 18385853 | 8-((2-HYDROXY-5-METHYLPHENYL)DIAZENYL)NAPHTHALENE-1,3-DISULFONIC ACID AS AN ANTIOXIDANT COMPOUND | October 2023 | January 2024 | Allow | 3 | 1 | 0 | No | No |
| 18385147 | 8-(4-CHLOROBENZYLIDENEAMINO)NAPHTHALENE-1,3-DISULFONIC ACID AS AN ANTIOXIDANT COMPOUND | October 2023 | March 2024 | Allow | 5 | 1 | 0 | No | No |
| 18385216 | 8-(3-CHLOROBENZYLIDENEAMINO)NAPHTHALENE-1,3-DISULFONIC ACID AS AN ANTIOXIDANT COMPOUND | October 2023 | February 2024 | Allow | 4 | 1 | 0 | No | No |
| 18382915 | 2-(BENZO[D]OXAZOL-2-YL)-N'-(4-(DIMETHYLAMINO)BENZOYLOXY)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | October 2023 | January 2024 | Allow | 2 | 0 | 0 | No | No |
| 18372771 | ARYL ALKYNAMIDE DERIVATIVES | September 2023 | November 2023 | Allow | 1 | 0 | 0 | Yes | No |
| 18242235 | 4-(1-(2-HYDROXYPROPYL)-4,5-DIPHENYL-1H-IMIDAZOL-2-YL)PYRIDIN-3-OL AS AN ANTIMICROBIAL COMPOUND | September 2023 | February 2024 | Allow | 6 | 0 | 1 | No | No |
| 18237710 | ENHANCEMENT OF CURCUMIN PLASMA LEVELS USING EUCALYPTOL CO-ADMINISTRATION | August 2023 | April 2024 | Allow | 8 | 3 | 0 | No | No |
| 18363942 | CRYSTALLINE FORMS OF A NEUROACTIVE STEROID | August 2023 | December 2023 | Allow | 4 | 0 | 0 | No | No |
| 18138244 | ENHANCEMENT OF CURCUMIN PLASMA LEVELS USING EUCALYPTOL COADMINISTRATION | April 2023 | August 2024 | Abandon | 16 | 3 | 0 | No | No |
| 18166478 | FULL CONTINUOUS-FLOW PREPARATION METHOD OF VITAMIN B1 | February 2023 | September 2023 | Allow | 7 | 0 | 0 | No | No |
| 18057861 | BEZOXAZINE DERIVATIVES USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | November 2022 | May 2024 | Abandon | 18 | 1 | 1 | No | No |
| 17975310 | PHOTOACTIVE FLUOROPHORES AND METHODS OF IN VIVO LABELING | October 2022 | January 2024 | Allow | 14 | 2 | 1 | Yes | No |
| 17957851 | COMPOSITIONS AND METHODS FOR TREATING HEADACHES | September 2022 | March 2024 | Abandon | 18 | 1 | 0 | No | No |
| 17856761 | SUBSTITUTED PYRIMIDINES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF | July 2022 | February 2024 | Allow | 20 | 1 | 1 | Yes | No |
| 17806990 | PRODRUGS, ANALOGS OR DERIVATIVES OF ANTHOCYANIDIN AS ANTIVIRAL AGENTS | June 2022 | July 2024 | Abandon | 25 | 0 | 2 | No | No |
| 17761501 | EPOXIDE WITH LOW TOTAL CHLORINE CONTENT AND NO HEAVY METAL RESIDUES AND PREPARATION METHOD THEREOF | March 2022 | February 2024 | Allow | 23 | 2 | 1 | No | No |
| 17665366 | EXTERNAL PREPARATION OF IMIDACLOPRID, PREPARATION METHOD AND USE THEREOF | February 2022 | June 2024 | Abandon | 29 | 1 | 1 | No | No |
| 17631898 | PURIFICATION OF AROMA CHEMICALS | February 2022 | May 2024 | Allow | 27 | 1 | 0 | No | No |
| 17504307 | HETEROARYL-THIO-SUBSTITUTED PYRONES | October 2021 | May 2024 | Allow | 31 | 2 | 1 | Yes | No |
| 17500681 | DIRECT AMPK ACTIVATORS | October 2021 | July 2024 | Abandon | 33 | 0 | 1 | No | No |
| 17449131 | FUSED IMIDAZO-PIPERIDINE JAK INHIBITOR COMPOUND | September 2021 | March 2024 | Allow | 30 | 0 | 0 | No | No |
| 17464598 | HIGHLY POLARIZABLE 3D ORGANIC PEROVSKITES AND ELECTRO-OPTIC MATERIALS COMPRISING SAME | September 2021 | August 2023 | Allow | 23 | 0 | 1 | No | No |
| 17428415 | METHOD FOR PREPARING EFINACONAZOLE USING IONIC LIQUID AS MEDIUM | August 2021 | February 2024 | Allow | 30 | 1 | 1 | No | No |
| 17426971 | HETEROCYCLIC COMPOUND | July 2021 | April 2024 | Allow | 33 | 0 | 0 | Yes | No |
| 17365213 | Compounds and Methods for the Treatment of COVID-19 | July 2021 | December 2023 | Allow | 29 | 1 | 0 | No | No |
| 17312195 | METHOD FOR PREPARING BRIVARACETAM AND INTERMEDIATE THEREOF | June 2021 | August 2024 | Allow | 38 | 1 | 0 | No | No |
| 17343016 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | June 2021 | May 2024 | Abandon | 35 | 1 | 0 | No | No |
| 17311746 | SOLID STATE FORMS OF REPROXALAP | June 2021 | May 2024 | Allow | 35 | 0 | 1 | Yes | No |
| 17335196 | IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | June 2021 | March 2024 | Allow | 34 | 0 | 0 | No | No |
| 17332324 | TRIAZOLE BISPHOSPHONATE GERANYLGERANYL DIPHOSPHATE SYNTHASE INHIBITORS | May 2021 | May 2024 | Allow | 35 | 1 | 1 | No | No |
| 17295789 | N-TRIFLUORMETHYLCARBONYL COMPOUNDS AND METHODS FOR THEIR SYNTHESIS | May 2021 | April 2024 | Abandon | 35 | 1 | 1 | No | No |
| 17318672 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF | May 2021 | June 2024 | Abandon | 37 | 0 | 1 | No | No |
| 17288351 | Methods of Treating Diseases Using Kinase Modulators | April 2021 | September 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17287442 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | April 2021 | April 2024 | Allow | 35 | 1 | 0 | No | No |
| 17226359 | GRP94 SELECTIVE INHIBITORS AND USES THEREOF | April 2021 | November 2023 | Allow | 31 | 0 | 1 | No | No |
| 17283049 | PRODRUGS OF CGRP ANTAGONISTS | April 2021 | March 2024 | Allow | 35 | 1 | 0 | Yes | No |
| 17282274 | Photoresponsive Nutlin Derivatives and Uses Thereof | April 2021 | February 2024 | Allow | 34 | 1 | 0 | No | No |
| 17281544 | PREPARATION METHOD FOR EFINACONAZOLE | March 2021 | October 2024 | Abandon | 42 | 2 | 1 | No | No |
| 17279471 | CRYSTAL FORM OF UPADACITINIB AND PREPARATION METHOD AND USE THEREOF | March 2021 | August 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17271966 | INHIBITION OF RIP KINASES FOR TREATING NEURODEGENERATIVE DISORDERS | February 2021 | September 2024 | Abandon | 43 | 2 | 1 | No | No |
| 17177617 | CHEMICAL COMPOUNDS | February 2021 | April 2024 | Allow | 38 | 1 | 1 | No | No |
| 17267866 | NOVEL SUBSTITUTED TETRAHYDROQUINOLINE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | February 2021 | January 2024 | Allow | 35 | 1 | 0 | Yes | No |
| 17265986 | PYRIDINE MACROCYCLE COMPOUNDS AS ASK1 INHIBITING AGENTS | February 2021 | October 2023 | Allow | 32 | 0 | 0 | Yes | No |
| 17263177 | PYRIDINYLMETHYLENEPIPERIDINE DERIVATIVES AND USES THEREOF | January 2021 | October 2023 | Allow | 33 | 0 | 0 | Yes | No |
| 17263416 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUND AS JAK INHIBITOR AND USE THEREOF | January 2021 | December 2023 | Allow | 34 | 1 | 0 | No | No |
| 17153593 | PROCESS FOR THE PREPARATION OF BACLOFEN AND ITS INTERMEDIATE | January 2021 | July 2024 | Abandon | 42 | 1 | 1 | No | No |
| 17259565 | METHOD OF PREPARING MALONONITRILE OXIME ETHER COMPOUND AND INTERMEDIATE COMPOUND | January 2021 | November 2023 | Allow | 35 | 2 | 1 | No | No |
| 17143602 | SALTS AND CRYSTAL FORMS OF GABA-A POSITIVE ALLOSTERIC MODULATOR | January 2021 | May 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17254914 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | December 2020 | August 2023 | Allow | 32 | 0 | 0 | Yes | No |
| 17124346 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | December 2020 | August 2024 | Abandon | 44 | 1 | 1 | No | No |
| 17117916 | DEUTERATED DERIVATIVES OF PSILOCYBIN AND USES THEREOF | December 2020 | March 2021 | Allow | 3 | 1 | 0 | No | No |
| 17053683 | SULFORHODAMINE PHOSPHORAMIDITE DYES | November 2020 | April 2024 | Allow | 41 | 1 | 1 | No | No |
| 17089058 | Tricyclic Benzoxaborole Compounds and Uses Thereof | November 2020 | March 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17068985 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | October 2020 | July 2021 | Allow | 9 | 2 | 0 | No | No |
| 16892786 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | June 2020 | July 2020 | Allow | 1 | 0 | 0 | No | No |
| 16888040 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | May 2020 | July 2020 | Allow | 1 | 0 | 0 | No | No |
| 16880337 | NOVEL CHIRAL N-ACYL-5,6,7(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-A]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF | May 2020 | October 2020 | Allow | 5 | 1 | 0 | No | No |
| 16835938 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | March 2020 | March 2021 | Allow | 11 | 1 | 0 | No | No |
| 16774268 | CHEMICAL COMPOUNDS | January 2020 | November 2020 | Allow | 10 | 1 | 0 | No | No |
| 16633263 | PROCESS FOR THE PREPARATION OF GLYCOPYRROLATE TOSYLATE | January 2020 | October 2020 | Allow | 9 | 0 | 0 | No | No |
| 16719805 | ETHER COMPOUNDS AND USES THEREOF | December 2019 | September 2020 | Allow | 9 | 1 | 0 | No | No |
| 16698057 | SALTS AND CRYSTAL FORMS OF GABA-A POSITIVE ALLOSTERIC MODULATOR | November 2019 | October 2020 | Allow | 10 | 1 | 0 | No | No |
| 16695253 | Tricyclic Benzoxaborole Compounds and Uses Thereof | November 2019 | August 2020 | Allow | 8 | 1 | 0 | No | No |
| 16687474 | MODULATORS OF HEMOGLOBIN | November 2019 | January 2020 | Allow | 2 | 0 | 0 | No | No |
| 16662997 | PARG INHIBITORY COMPOUNDS | October 2019 | December 2020 | Allow | 14 | 1 | 0 | No | No |
| 16607609 | METHODS OF USE FOR TRISUBSTITUTED BENZOTRIAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS | October 2019 | February 2021 | Allow | 16 | 1 | 0 | No | No |
| 16660411 | ZIRCONIUM METAL-ORGANIC FRAMEWORK AND A METHOD OF DETECTING COPPER AND CHROMATE IONS | October 2019 | December 2020 | Allow | 13 | 1 | 0 | No | No |
| 16656940 | FUSED IMIDAZO-PIPERIDINE JAK INHIBITOR COMPOUND | October 2019 | July 2021 | Allow | 21 | 0 | 0 | No | No |
| 16655636 | METHOD FOR PREPARING SODIUM NITROTETROZOLATE USING CATION EXCHANGE RESIN | October 2019 | November 2020 | Allow | 13 | 0 | 1 | No | No |
| 16654281 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | October 2019 | March 2020 | Allow | 5 | 0 | 0 | No | No |
| 16605564 | TRIAZOLE BISPHOSPHONATE GERANYLGERANYL DIPHOSPHATE SYNTHASE INHIBITORS | October 2019 | February 2021 | Allow | 16 | 1 | 0 | No | No |
| 16579150 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | September 2019 | December 2019 | Allow | 3 | 0 | 0 | No | No |
| 16578276 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | September 2019 | September 2020 | Allow | 12 | 0 | 0 | No | No |
| 16496031 | HYDRATED CRYSTALLINE FORM OF 2-ACRYLAMIDO-2-METHYLPROPANE SULFONIC ACID | September 2019 | June 2020 | Allow | 9 | 1 | 0 | Yes | No |
| 16492434 | CATHEPSIN-D AND ANGIOGENESIS INHIBITORS AND COMPOSITIONS THEREOF FOR TREATING BREAST CANCER | September 2019 | November 2020 | Allow | 14 | 1 | 0 | No | No |
| 16491642 | MANUFACTURE OF A CRYSTALLINE PHARMACEUTICAL PRODUCT | September 2019 | July 2021 | Allow | 22 | 1 | 1 | No | No |
| 16491459 | AMINOPYRIMIDINE FIVE-MEMBERED HETEROCYCLIC COMPOUND, AND INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | September 2019 | March 2021 | Allow | 18 | 1 | 1 | No | No |
| 16491185 | AMINE SALT OF (1R, 3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOL-2-YLCARBAMOYL)CYCLOPENTANE CARBOXYLIC ACID | September 2019 | December 2019 | Allow | 3 | 0 | 0 | No | No |
| 16560087 | CRYSTALLINE FORMS OF A PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITOR | September 2019 | July 2021 | Allow | 23 | 1 | 0 | No | No |
| 16551694 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | August 2019 | December 2019 | Allow | 3 | 0 | 0 | No | No |
| 16487441 | PROCESS FOR THE PREPARATION OF 2-CYANOIMIDAZOLE COMPOUNDS | August 2019 | January 2021 | Allow | 17 | 1 | 1 | No | No |
| 16486031 | POLYFLUOROALKYL PHOSPHORIC ACID ESTER OR SALT THEREOF, AND MOLD-RELEASING AGENT COMPRISING THE SAME AS AN ACTIVE INGREDIENT | August 2019 | May 2020 | Allow | 9 | 0 | 0 | No | No |
| 16540747 | Arginase Inhibitors and Their Therapeutic Applications | August 2019 | September 2020 | Allow | 13 | 1 | 1 | No | No |
| 16484938 | PROCESS FOR PREPARING BRIVARACETAM | August 2019 | February 2021 | Abandon | 18 | 2 | 0 | No | No |
| 16532106 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | August 2019 | November 2019 | Allow | 4 | 0 | 0 | No | No |
| 16483341 | ANTI-FIBROTIC COMPOUNDS | August 2019 | January 2021 | Allow | 17 | 1 | 1 | No | No |
| 16482947 | COMPOSITIONS AND METHODS FOR INHIBITING RETICULON 4 | August 2019 | February 2021 | Abandon | 19 | 0 | 1 | No | No |
| 16527171 | C17-HETEROARYL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF | July 2019 | September 2020 | Allow | 14 | 1 | 0 | No | No |
| 16524618 | 2-OXINDOLE COMPOUNDS | July 2019 | April 2020 | Allow | 9 | 0 | 0 | No | No |
| 16521691 | STEREOCHEMICALLY DEFINED POLYPROPIONATES AND METHODS FOR MAKING AND USING THE SAME | July 2019 | May 2020 | Allow | 10 | 1 | 0 | No | No |
| 16517369 | SALTS AND CRYSTAL FORMS OF GABA-A POSITIVE ALLOSTERIC MODULATOR | July 2019 | November 2019 | Allow | 4 | 0 | 0 | No | No |
| 16514413 | COMPOUNDS I | July 2019 | February 2021 | Allow | 19 | 1 | 1 | No | No |
| 16509388 | MEROPENEM DERIVATIVES AND USES THEREOF | July 2019 | April 2021 | Allow | 21 | 2 | 1 | No | No |
| 16475672 | METHOD OF ADMINISTERING NITROXYL DONATING COMPOUNDS | July 2019 | September 2020 | Allow | 15 | 0 | 0 | No | No |
| 16448066 | NOVEL COMPOUNDS | June 2019 | May 2020 | Allow | 11 | 1 | 1 | No | No |
| 16446604 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | June 2019 | May 2020 | Allow | 11 | 1 | 1 | No | No |
| 16466107 | FRAGRANCE AND FLAVOR MATERIALS | June 2019 | January 2020 | Allow | 8 | 0 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHENG, KAREN.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 18.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner CHENG, KAREN works in Art Unit 1626 and has examined 545 patent applications in our dataset. With an allowance rate of 76.3%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 18 months.
Examiner CHENG, KAREN's allowance rate of 76.3% places them in the 34% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by CHENG, KAREN receive 1.17 office actions before reaching final disposition. This places the examiner in the 19% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by CHENG, KAREN is 18 months. This places the examiner in the 93% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +25.4% benefit to allowance rate for applications examined by CHENG, KAREN. This interview benefit is in the 76% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 33.2% of applications are subsequently allowed. This success rate is in the 65% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 52.6% of cases where such amendments are filed. This entry rate is in the 73% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 150.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 88% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 87.5% of appeals filed. This is in the 78% percentile among all examiners. Of these withdrawals, 85.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 44.9% are granted (fully or in part). This grant rate is in the 50% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 1.1% of allowed cases (in the 69% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.9% of allowed cases (in the 65% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.